ClinicalTrials.gg

Program

AZD2389

A development code.

Its studies are mostly in Liver Cirrhosis · Lymphoma, Follicular · Liver Diseases, led by AstraZeneca.

Furthest: phase 2, since Dec 6, 20248 company-led studies, 1 open or runningNext primary completion: Jul 7, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca81 open or runningphase 2since Dec 6, 2024Nov 14, 2023Jul 7, 2027phase 2 · NCT07610837
  • Named in AstraZeneca’s own pipeline as AZD2389, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: ctc-clinical-trial-consultants-ab and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2023First study: phase 1 study in Liver DiseasesFirst studyNCT06138795 · 120 enrolled · United States
  2. Dec 6, 2024Phase 2 study in Liver CirrhosisNCT06750276 · 40 enrolled · United States, Puerto Rico, United Kingdom
  3. Feb 3, 20252 phase 1 studiesNCT06812780, NCT06846528
  4. May 7, 20253 phase 1 studies in Liver CirrhosisNCT06973005, NCT06974565, NCT07069725
  5. Apr 30, 2026Phase 2 study in Liver CirrhosisNCT07610837 · 104 planned · United States, Puerto Rico

Ahead

  1. Jul 7, 2027Primary completion: phase 2 study in Liver CirrhosisNCT07610837

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07610837Liver Cirrhosis · United States, Puerto Rico2RecruitingJul 7, 2027104
NCT07069725Liver Cirrhosis · Sweden1CompletedJul 2, 20268
NCT06974565Liver Cirrhosis · United States1CompletedJul 18, 202516
NCT06973005Liver Cirrhosis · United States1CompletedJul 18, 202516
NCT06846528Healthy Participants · United States1CompletedApr 23, 202516
NCT06812780Lymphoma, Follicular · United States1CompletedSep 4, 202535
NCT06750276Liver Cirrhosis · United States, Puerto Rico, United Kingdom2CompletedJul 28, 202540
NCT06138795Liver Diseases · United States1CompletedAug 24, 2025120

How it is read

Names in the registry

  • “AZD2389”, 8 entries

Codes read as this program: AZD2389.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.